Abstract Body

Background: Urolithiasis have been reported in patients treated with ATV. Risk factors, clinical features and outcome of ATV-associated urolithiasis have not been fully investigated. Methodology: From January 2008 to December 2012, we collected all cases of ATV-associated urolithiasis among HIV-infected patients receiving ATV-containing regimens in Paris. A case-control study was then performed with cases defined as adults in whom an ATV-containing urolithiasis had been identified by spectroscopic analysis. Three controls per case were randomly selected among patients treated with ATV-based regimens for at least 6 months and no history of ATV-associated urolithiasis. Patients characteristics, treatment and outcome were retrieved from medical charts at diagnosis and 6-12 months later. An univariate logistic regression analysis was carried out to identify factors associated with the occurrence of ATV-containing urolithiasis and all factors with p-value < 0.20 were kept for a multivariate model selection. Results: Thirty cases were analyzed. Patients were mostly men (87%), with a median age of 45.5 years, a median CD4 cell count of 443 cells/μL. 97% had plasma HIV RNA levels < 50 cp/mL. Median time between the initiation of ATV-containing regimen and the diagnosis of urolithiasis was 3.1 years [IQR: 2.2-3.8]. Clinical symptoms leading to diagnosis were flank pain in 90% and hematuria in 63%. At diagnosis, renal failure (MDRD creatinine clearance <60 mL/min) was reported in 16/30 (53%) of patients. Ureteroscopic treatment was required in 48% (14/29) of patients and a double J catheter was left in place in 29% (8/28) of cases. 6-12 months after the episode, creatinine clearance remained < 60 mL/min in 5/13 (38.5%) patients. Factors associated with urolithiasis in the univariate analysis were a history of urinary lithiasis (OR=6.86 (95% CI=2.35, 20.03), p<0.001), the use of ritonavir as ATV-booster (OR=9.38 (95% CI: 1.21, 72.9), p<0.04), previous indinavir use (OR 3.25 (95%CI: 1.33, 7.96), p<0.01), duration of exposure to ATV (OR=1.37 per year (95% CI=1.04, 1.79), p<0.03) and serum bilirubin levels (OR=2.08 per 2-fold increase (95% CI=1.19, 3.61), p<0.01). The final multivariate model identified serum bilirubin (OR=2.66 per 2-fold increase (95% CI=1.35, 5.21), p<0.01) and duration of exposure to ATV (OR=1.42 per year (95% CI=1.04, 1.93), p<0.03) as independent risk factors. Conclusions: Although rare, ATV-containing urolithiasis can be associated with severe renal dysfunction and may require surgical treatment. A high serum bilirubin level and long exposure to ATV-containing regimens are independent risk factors for this complication.